Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose propiverine + alpha-antagonist vs alpha-antagonist alone in men with BPH and overactive bladder
KCT0000077Phase 4Recruiting
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Start
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of propiverine in benign prostatic hyperplasia (BPH), overactive bladder (OAB) and urinary bladder diseases (3 arms), sponsored by Jeil Pharmaceutical Co., Ltd. Started Jan 2011; status: recruiting.
02
Drugs
propiverine
03
Conditions
benign prostatic hyperplasia (BPH)overactive bladder (OAB)urinary bladder diseases
Beyond the preview
Go deeper on KCT0000077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0000077.